00022101T: Development of Anti-Canine Il-2R? Antibodies Using CpG Oligodeoxynucleotide Vaccination
Grant Status: Closed
Abstract
Despite progress in treating canine lymphoma, most affected dogs eventually develop resistance to chemotherapy and succumb to their disease. In human medicine, the a subunit of the interleukin-2 receptor (IL-2Ra ) has been developed as a target for immunotherapy of chemoresistant lymphoma patients. Intensively studied as a molecule present on normal lymphocytes that are activated, IL-2Ra has recently been developed as a target on malignant lymphocytes that have been found to express this protein inappropriately. This has been accomplished using anti-IL-2Ra monoclonal antibody (Mab) to deliver cellular toxins or radioisotopes directly to the cancer cells, a strategy that overcomes drug resistance. We would now like to develop such an antibody against the canine Il-2Rasubunit that could benefit dogs with lymphoma. Our rationale for pursuing this approach stems from molecular data we generated indicating that a high percentage of canine lymphomas from Golden Retrievers and Rottweilers express Il-2Ra Having synthesized canine recombinant (cr) IL-2R?a using the gene sequence we cloned, we are now ready to produce and validate Mabs against it. To accomplish these goals, 1) we will employ a novel immunization strategy to prepare murine anti-canine IL-2Ra Mabs, 2) develop a test using anti-canine IL-2Ra Mabs for the detection of IL-2R?ashed into the blood of Golden Retriever and Rottweiler lymphoma patients, and 3) screen lymphoma biopsies from Golden Retrievers and Rottweilers for IL-2Ra. Mabs generated to Canine IL-2R?a will be a powerful tool in the diagnosis, prognosis, and treatment of canine lymphoma.
Publication(s)
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
